WHO To Revisit Guidelines On Ebola Survivors’ Care; Study Finds 5-fold Higher Mortality 06/09/2019 Grace Ren New data revealing that survivors of Guinea’s 2013-16 Ebola outbreak were five times more likely to die within the first year after recovery, as compared to the general population, suggests a need to revisit WHO guidance on Ebola survivors’ monitoring and care, a top WHO official said on Friday. The findings were part of a […] Continue reading -> Facebook Moves To Squash Vaccine Misinformation; WHO Website Now A Top Pick 05/09/2019 Elaine Ruth Fletcher Facebook has begun rolling out a new algorithm that directs users searching for vaccine information to the United States Centers for Disease Control (CDC) website, in the case of US-based searches, and for users elsewhere, the World Health Organization website, as a top search pick. The move was welcomed by WHO, officials at CDC, and […] Continue reading -> FDA Approves New Treatment For Drug-Resistant TB; Activists Call For Affordable Access 19/08/2019 Grace Ren The US Food and Drug Administration (FDA) last week approved a tuberculosis (TB) treatment regimen containing a new drug, pretomanid, offering a shorter, more effective course of treatment for highly drug-resistant strains of TB, the world’s leading cause of death by infectious disease. Pretomanid is only the third TB drug to be approved in over […] Continue reading -> How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Ebola Outbreak Marks 1 Year With Huge Funding Gap, Questions On Vaccine Strategy 01/08/2019 David Branigan Thursday, 1 August, marked the one-year anniversary of the Ebola outbreak in the Democratic Republic of the Congo (DRC), as daily reports of new infections, including 3 more cases in Goma along DRC’s border with Rwanda, fueled new concerns about regional spread of the deadly disease. Meanwhile, the World Health Organization called on international donors […] Continue reading -> WHO Calls On Countries To Scale Up Hepatitis Services, Invest In Elimination 29/07/2019 David Branigan 80 percent of people with viral hepatitis lack access to services for prevention, testing & treatment. To address this gap, the World Health Organization calls on countries to invest in scaling up hepatitis services as part of their universal health coverage (UHC) plans. On the occasion of World Hepatitis Day (28 July), WHO raised alarm […] Continue reading -> Gavi Says 1.3 Million Doses Of Merck’s Ebola Vaccine Will Be Made Available; MSF Says Field Supply “Extremely Low” & “Sporadic” 23/07/2019 Elaine Ruth Fletcher There is no shortage of Merck’s life-saving Ebola vaccine on the ground in the Democratic Republic of Congo, and more doses will be produced, sufficient to immunise 1.3 million people over the next 6-18 months, a spokesman for Gavi, the Vaccine Alliance, told Health Policy Watch on Tuesday. Meanwhile, Merck, producer of the V920 investigational […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Facebook Moves To Squash Vaccine Misinformation; WHO Website Now A Top Pick 05/09/2019 Elaine Ruth Fletcher Facebook has begun rolling out a new algorithm that directs users searching for vaccine information to the United States Centers for Disease Control (CDC) website, in the case of US-based searches, and for users elsewhere, the World Health Organization website, as a top search pick. The move was welcomed by WHO, officials at CDC, and […] Continue reading -> FDA Approves New Treatment For Drug-Resistant TB; Activists Call For Affordable Access 19/08/2019 Grace Ren The US Food and Drug Administration (FDA) last week approved a tuberculosis (TB) treatment regimen containing a new drug, pretomanid, offering a shorter, more effective course of treatment for highly drug-resistant strains of TB, the world’s leading cause of death by infectious disease. Pretomanid is only the third TB drug to be approved in over […] Continue reading -> How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Ebola Outbreak Marks 1 Year With Huge Funding Gap, Questions On Vaccine Strategy 01/08/2019 David Branigan Thursday, 1 August, marked the one-year anniversary of the Ebola outbreak in the Democratic Republic of the Congo (DRC), as daily reports of new infections, including 3 more cases in Goma along DRC’s border with Rwanda, fueled new concerns about regional spread of the deadly disease. Meanwhile, the World Health Organization called on international donors […] Continue reading -> WHO Calls On Countries To Scale Up Hepatitis Services, Invest In Elimination 29/07/2019 David Branigan 80 percent of people with viral hepatitis lack access to services for prevention, testing & treatment. To address this gap, the World Health Organization calls on countries to invest in scaling up hepatitis services as part of their universal health coverage (UHC) plans. On the occasion of World Hepatitis Day (28 July), WHO raised alarm […] Continue reading -> Gavi Says 1.3 Million Doses Of Merck’s Ebola Vaccine Will Be Made Available; MSF Says Field Supply “Extremely Low” & “Sporadic” 23/07/2019 Elaine Ruth Fletcher There is no shortage of Merck’s life-saving Ebola vaccine on the ground in the Democratic Republic of Congo, and more doses will be produced, sufficient to immunise 1.3 million people over the next 6-18 months, a spokesman for Gavi, the Vaccine Alliance, told Health Policy Watch on Tuesday. Meanwhile, Merck, producer of the V920 investigational […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
FDA Approves New Treatment For Drug-Resistant TB; Activists Call For Affordable Access 19/08/2019 Grace Ren The US Food and Drug Administration (FDA) last week approved a tuberculosis (TB) treatment regimen containing a new drug, pretomanid, offering a shorter, more effective course of treatment for highly drug-resistant strains of TB, the world’s leading cause of death by infectious disease. Pretomanid is only the third TB drug to be approved in over […] Continue reading -> How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Ebola Outbreak Marks 1 Year With Huge Funding Gap, Questions On Vaccine Strategy 01/08/2019 David Branigan Thursday, 1 August, marked the one-year anniversary of the Ebola outbreak in the Democratic Republic of the Congo (DRC), as daily reports of new infections, including 3 more cases in Goma along DRC’s border with Rwanda, fueled new concerns about regional spread of the deadly disease. Meanwhile, the World Health Organization called on international donors […] Continue reading -> WHO Calls On Countries To Scale Up Hepatitis Services, Invest In Elimination 29/07/2019 David Branigan 80 percent of people with viral hepatitis lack access to services for prevention, testing & treatment. To address this gap, the World Health Organization calls on countries to invest in scaling up hepatitis services as part of their universal health coverage (UHC) plans. On the occasion of World Hepatitis Day (28 July), WHO raised alarm […] Continue reading -> Gavi Says 1.3 Million Doses Of Merck’s Ebola Vaccine Will Be Made Available; MSF Says Field Supply “Extremely Low” & “Sporadic” 23/07/2019 Elaine Ruth Fletcher There is no shortage of Merck’s life-saving Ebola vaccine on the ground in the Democratic Republic of Congo, and more doses will be produced, sufficient to immunise 1.3 million people over the next 6-18 months, a spokesman for Gavi, the Vaccine Alliance, told Health Policy Watch on Tuesday. Meanwhile, Merck, producer of the V920 investigational […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Ebola Outbreak Marks 1 Year With Huge Funding Gap, Questions On Vaccine Strategy 01/08/2019 David Branigan Thursday, 1 August, marked the one-year anniversary of the Ebola outbreak in the Democratic Republic of the Congo (DRC), as daily reports of new infections, including 3 more cases in Goma along DRC’s border with Rwanda, fueled new concerns about regional spread of the deadly disease. Meanwhile, the World Health Organization called on international donors […] Continue reading -> WHO Calls On Countries To Scale Up Hepatitis Services, Invest In Elimination 29/07/2019 David Branigan 80 percent of people with viral hepatitis lack access to services for prevention, testing & treatment. To address this gap, the World Health Organization calls on countries to invest in scaling up hepatitis services as part of their universal health coverage (UHC) plans. On the occasion of World Hepatitis Day (28 July), WHO raised alarm […] Continue reading -> Gavi Says 1.3 Million Doses Of Merck’s Ebola Vaccine Will Be Made Available; MSF Says Field Supply “Extremely Low” & “Sporadic” 23/07/2019 Elaine Ruth Fletcher There is no shortage of Merck’s life-saving Ebola vaccine on the ground in the Democratic Republic of Congo, and more doses will be produced, sufficient to immunise 1.3 million people over the next 6-18 months, a spokesman for Gavi, the Vaccine Alliance, told Health Policy Watch on Tuesday. Meanwhile, Merck, producer of the V920 investigational […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Ebola Outbreak Marks 1 Year With Huge Funding Gap, Questions On Vaccine Strategy 01/08/2019 David Branigan Thursday, 1 August, marked the one-year anniversary of the Ebola outbreak in the Democratic Republic of the Congo (DRC), as daily reports of new infections, including 3 more cases in Goma along DRC’s border with Rwanda, fueled new concerns about regional spread of the deadly disease. Meanwhile, the World Health Organization called on international donors […] Continue reading -> WHO Calls On Countries To Scale Up Hepatitis Services, Invest In Elimination 29/07/2019 David Branigan 80 percent of people with viral hepatitis lack access to services for prevention, testing & treatment. To address this gap, the World Health Organization calls on countries to invest in scaling up hepatitis services as part of their universal health coverage (UHC) plans. On the occasion of World Hepatitis Day (28 July), WHO raised alarm […] Continue reading -> Gavi Says 1.3 Million Doses Of Merck’s Ebola Vaccine Will Be Made Available; MSF Says Field Supply “Extremely Low” & “Sporadic” 23/07/2019 Elaine Ruth Fletcher There is no shortage of Merck’s life-saving Ebola vaccine on the ground in the Democratic Republic of Congo, and more doses will be produced, sufficient to immunise 1.3 million people over the next 6-18 months, a spokesman for Gavi, the Vaccine Alliance, told Health Policy Watch on Tuesday. Meanwhile, Merck, producer of the V920 investigational […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Ebola Outbreak Marks 1 Year With Huge Funding Gap, Questions On Vaccine Strategy 01/08/2019 David Branigan Thursday, 1 August, marked the one-year anniversary of the Ebola outbreak in the Democratic Republic of the Congo (DRC), as daily reports of new infections, including 3 more cases in Goma along DRC’s border with Rwanda, fueled new concerns about regional spread of the deadly disease. Meanwhile, the World Health Organization called on international donors […] Continue reading -> WHO Calls On Countries To Scale Up Hepatitis Services, Invest In Elimination 29/07/2019 David Branigan 80 percent of people with viral hepatitis lack access to services for prevention, testing & treatment. To address this gap, the World Health Organization calls on countries to invest in scaling up hepatitis services as part of their universal health coverage (UHC) plans. On the occasion of World Hepatitis Day (28 July), WHO raised alarm […] Continue reading -> Gavi Says 1.3 Million Doses Of Merck’s Ebola Vaccine Will Be Made Available; MSF Says Field Supply “Extremely Low” & “Sporadic” 23/07/2019 Elaine Ruth Fletcher There is no shortage of Merck’s life-saving Ebola vaccine on the ground in the Democratic Republic of Congo, and more doses will be produced, sufficient to immunise 1.3 million people over the next 6-18 months, a spokesman for Gavi, the Vaccine Alliance, told Health Policy Watch on Tuesday. Meanwhile, Merck, producer of the V920 investigational […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Ebola Outbreak Marks 1 Year With Huge Funding Gap, Questions On Vaccine Strategy 01/08/2019 David Branigan Thursday, 1 August, marked the one-year anniversary of the Ebola outbreak in the Democratic Republic of the Congo (DRC), as daily reports of new infections, including 3 more cases in Goma along DRC’s border with Rwanda, fueled new concerns about regional spread of the deadly disease. Meanwhile, the World Health Organization called on international donors […] Continue reading -> WHO Calls On Countries To Scale Up Hepatitis Services, Invest In Elimination 29/07/2019 David Branigan 80 percent of people with viral hepatitis lack access to services for prevention, testing & treatment. To address this gap, the World Health Organization calls on countries to invest in scaling up hepatitis services as part of their universal health coverage (UHC) plans. On the occasion of World Hepatitis Day (28 July), WHO raised alarm […] Continue reading -> Gavi Says 1.3 Million Doses Of Merck’s Ebola Vaccine Will Be Made Available; MSF Says Field Supply “Extremely Low” & “Sporadic” 23/07/2019 Elaine Ruth Fletcher There is no shortage of Merck’s life-saving Ebola vaccine on the ground in the Democratic Republic of Congo, and more doses will be produced, sufficient to immunise 1.3 million people over the next 6-18 months, a spokesman for Gavi, the Vaccine Alliance, told Health Policy Watch on Tuesday. Meanwhile, Merck, producer of the V920 investigational […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO Calls On Countries To Scale Up Hepatitis Services, Invest In Elimination 29/07/2019 David Branigan 80 percent of people with viral hepatitis lack access to services for prevention, testing & treatment. To address this gap, the World Health Organization calls on countries to invest in scaling up hepatitis services as part of their universal health coverage (UHC) plans. On the occasion of World Hepatitis Day (28 July), WHO raised alarm […] Continue reading -> Gavi Says 1.3 Million Doses Of Merck’s Ebola Vaccine Will Be Made Available; MSF Says Field Supply “Extremely Low” & “Sporadic” 23/07/2019 Elaine Ruth Fletcher There is no shortage of Merck’s life-saving Ebola vaccine on the ground in the Democratic Republic of Congo, and more doses will be produced, sufficient to immunise 1.3 million people over the next 6-18 months, a spokesman for Gavi, the Vaccine Alliance, told Health Policy Watch on Tuesday. Meanwhile, Merck, producer of the V920 investigational […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Gavi Says 1.3 Million Doses Of Merck’s Ebola Vaccine Will Be Made Available; MSF Says Field Supply “Extremely Low” & “Sporadic” 23/07/2019 Elaine Ruth Fletcher There is no shortage of Merck’s life-saving Ebola vaccine on the ground in the Democratic Republic of Congo, and more doses will be produced, sufficient to immunise 1.3 million people over the next 6-18 months, a spokesman for Gavi, the Vaccine Alliance, told Health Policy Watch on Tuesday. Meanwhile, Merck, producer of the V920 investigational […] Continue reading -> ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
ReAct Africa Conference On Antimicrobial Resistance Opens in Nairobi 23/07/2019 Geoffrey Kamadi The 2019 ReAct Africa Conference on Antimicrobial Resistance (AMR), which opened Tuesday in Nairobi, Kenya, will focus on ways to advance universal health coverage while combating antimicrobial resistance (AMR) on the continent. Some 24 African countries are taking place in the three day event co-sponsored by the United Kingdom-based Fleming Fund dedicated to supporting low- […] Continue reading -> Posts navigation Older postsNewer posts